Extract

A number of studies have evaluated the effectiveness of a “Maintenance And Reliever Therapy” (MART) regimen combining in a single inhaler the rapid-acting, long-acting β₂-agonist (LABA) formoterol fumarate (FF) with an inhaled corticosteroid (ICS) in asthma [1–5]. Such a regimen is now established for the treatment of moderate-to-severe asthma in adolescents and adults in many guidelines [6, 7]. Furthermore, rescue short-acting β₂-agonists (SABAs) are no longer recommended as sole therapy even for patients with mild asthma, and an ICS/FF combination used as needed is the preferred reliever therapy [6].